Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Current practice of immune suppressive standard therapy after renal transplantation in
non-risk patients is a triple therapy consisting of steroids, a calcineurin inhibitor and
MMF. The aim of this clinical trial is to combine a reduction of CNI using tacrolimus and a
concept of not using steroids in order to establish an immunosuppressive regimen in
immunologically non-risk patients that is efficient and causes as few side effects as
possible.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Freiburg
Collaborators:
Astellas Pharma GmbH Genzyme, a Sanofi Company Roche Pharma AG